eif-3.C Antibody

What is eIF3C and what cellular functions does it regulate?

eIF3C is a subunit of the eukaryotic translation initiation factor 3 (eIF3) complex, which plays a critical role in translation initiation—the rate-limiting step of protein synthesis. The eIF3 complex functions in the assembly of the 43S pre-initiation complex and promotes mRNA binding to ribosomes. Recent research has shown that eIF3 engages with 3'-UTR termini of highly translated mRNAs, particularly adjacent to the poly(A) tail . This interaction appears to be dependent on polyadenylation but independent of direct interactions with poly(A)-binding proteins . eIF3C specifically functions within this complex and has been implicated in regulating cell proliferation, apoptosis, and tumorigenesis in various cancer types .

What is the molecular weight of eIF3C, and how can I confirm antibody specificity?

eIF3C has a molecular weight of approximately 110 kDa, which should be confirmed when validating antibody specificity via Western blotting . To verify antibody specificity:

• Run positive controls (cells known to express eIF3C) alongside experimental samples

• Include negative controls through:

  • siRNA knockdown of eIF3C

  • Cell lines with low/no expression

  • Secondary antibody-only controls

Validation data should show a single band at approximately 110 kDa in positive controls and reduced or absent signal in knockdown samples. Cross-reactivity with other proteins can be evaluated by comparing the banding pattern across multiple cell lines or tissues .

What species reactivity can I expect with commercial eIF3C antibodies?

Most commercially available eIF3C antibodies, including the Cell Signaling Technology #2068 antibody, demonstrate reactivity with human, mouse, and monkey samples . Reactivity across species stems from high sequence conservation of eIF3C epitopes. When planning cross-species experiments:

When working with species not explicitly listed in manufacturer specifications, sequence alignment of the immunogen region with your target species is recommended to predict potential cross-reactivity .

What are the optimal sample preparation conditions for detecting eIF3C?

For optimal detection of eIF3C in cell and tissue samples:

• Cell lysis buffer composition should include:

  • 50 mM Tris-HCl (pH 7.5)

  • 150 mM NaCl

  • 2 mM EDTA

  • 0.5% Nonidet P-40 alternative

  • 0.5 mM DTT

  • Protease inhibitor cocktail

• Protein extraction protocol:

  • Incubate cells in lysis buffer on ice for 10 minutes

  • Pass through an 18G needle four times to ensure complete lysis

  • Centrifuge at 13,000g for 10 minutes at 4°C to clear debris

  • Collect supernatant for immediate use or flash-freeze

• Protein quantification and loading:

  • Load 20-50 μg of total protein per lane

  • Run samples on 4-12% Bis-Tris gradient gels for optimal separation

These conditions maximize eIF3C protein stability and detection sensitivity while minimizing background in downstream applications.

How can I effectively use eIF3C antibodies to study its role in cancer biology?

eIF3C overexpression has been identified in multiple cancer types including glioma, head and neck carcinoma, and breast cancer . To investigate eIF3C's role in cancer:

• Expression analysis in clinical samples:

  • Perform immunohistochemistry with eIF3C antibody on tissue microarrays

  • Correlate expression levels with clinicopathological features and patient outcomes

  • Compare normal adjacent tissue with tumor tissue to establish baseline differences

• Functional studies using eIF3C knockdown:

  • Utilize lentivirus-mediated siRNA targeting eIF3C (L.v-shEIF3C) as demonstrated in pharyngeal squamous carcinoma cells

  • Confirm knockdown efficiency via both qRT-PCR and Western blotting

  • Assess effects on cell proliferation using multiple orthogonal assays:

    • Cellomics with GFP tracking

    • Colony formation assays

    • BrdU incorporation

• Cell cycle and apoptosis analysis:

  • Flow cytometry to measure cell cycle distribution changes

  • Annexin V/PI staining to quantify apoptotic cells

  • Western blot analysis of apoptotic markers

Results from these approaches can be integrated to establish a mechanistic understanding of eIF3C's contribution to cancer development and progression, as demonstrated in head and neck carcinoma studies where eIF3C knockdown significantly inhibited proliferation and induced apoptosis .

What are the technical considerations when performing co-immunoprecipitation with eIF3C antibodies?

Co-immunoprecipitation (Co-IP) with eIF3C antibodies requires careful optimization to maintain protein-protein interactions within the eIF3 complex and with other potential binding partners. Consider the following technical aspects:

• Crosslinking approaches:

  • For transient interactions, use reversible protein-protein crosslinkers like dithiobis(succinimidyl propionate) (DSP) at 1 mM

  • Quench reaction with 10 mM Tris-HCl, pH 7.5 for 15 minutes

  • For RNA-protein interactions, UV crosslinking or formaldehyde may be appropriate

• Immunoprecipitation protocol:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Use 5 μg of antibody per 1 mg of total protein

  • Include 5% input samples as controls

  • Incubate antibody-conjugated beads with lysate for 2-4 hours at 4°C with gentle rotation

  • Wash beads thoroughly with lysis buffer (3-5 times)

• Elution strategies:

  • For mass spectrometry applications, elute with 50 μL 1X NuPAGE LDS sample buffer

  • For crosslinked samples, include DTT to cleave the disulfide bond in DSP spacer arm

  • Boil samples at 70°C for 5 minutes to release bound proteins

• Control experiments:

  • Include IgG control IP to identify non-specific binding

  • Perform reciprocal IPs with antibodies against known interaction partners

  • Include RNase treatment controls if investigating RNA-dependent interactions

These considerations are essential for reliable identification of true eIF3C interactors versus background contaminants.

How do I optimize immunofluorescence protocols for eIF3C subcellular localization studies?

Subcellular localization of eIF3C provides valuable insights into its function in different cellular compartments. To optimize immunofluorescence:

• Fixation and permeabilization:

  • Test both paraformaldehyde (4%, 10 minutes) and methanol (100%, -20°C, 10 minutes) fixation

  • For paraformaldehyde fixation, permeabilize with 0.1-0.5% Triton X-100

  • Blocking should include 5% BSA or 10% normal serum in PBS for 1 hour

• Antibody dilutions and incubation:

  • Start with 1:100-1:500 dilution range for primary antibody

  • Incubate overnight at 4°C or 1-2 hours at room temperature

  • Use fluorophore-conjugated secondary antibodies at 1:500-1:1000

  • Include DAPI (1:1000) for nuclear counterstaining

• Co-localization studies:

  • Combine eIF3C antibody with markers for:

    • Ribosomes (anti-RPL7)

    • Processing bodies (anti-DCP1a)

    • Stress granules (anti-G3BP1)

    • ER (anti-calnexin)

  • Use sequential staining protocols if antibodies are from the same species

• Imaging considerations:

  • Acquire z-stacks for accurate co-localization analysis

  • Use deconvolution to improve signal-to-noise ratio

  • Quantify co-localization using Pearson's or Mander's coefficients

When interpreting results, note that eIF3C is primarily cytoplasmic but may show distinct localization patterns in "nascent" translation sites, especially in differentiating or stressed cells .

What approaches can be used to study eIF3C's role in mRNA binding and translational regulation?

Recent research has highlighted eIF3's engagement with 3'-UTR termini of highly translated mRNAs . To investigate eIF3C's specific role in this process:

• RNA immunoprecipitation (RIP) and crosslinking approaches:

  • Quick-irCLIP (individual-nucleotide resolution Cross-Linking and ImmunoPrecipitation) provides single-nucleotide resolution of RNA-protein interaction sites

  • Standard protocol includes:

    • UV crosslinking cells at 254 nm

    • Immunoprecipitation with eIF3C antibody

    • Partial RNA digestion

    • 3' adapter ligation to RNA fragments

    • RT-PCR and sequencing

• Alternative polyadenylation (APA) analysis:

  • Combine APA-Seq with eIF3C knockdown to identify affected transcripts

  • Compare 3'-UTR isoform usage between control and eIF3C-depleted cells

• Translational efficiency measurements:

  • Ribosome profiling to measure ribosome occupancy on mRNAs

  • Polysome profiling followed by RNA-seq to identify transcripts with altered translation

  • SUnSET (Surface Sensing of Translation) assay to measure global protein synthesis rates

• Mutational analysis:

  • Design mutations in potential RNA-binding domains of eIF3C

  • Assess impact on binding to specific mRNA targets

  • Evaluate functional consequences on translation of reporter constructs

Integration of these approaches can reveal how eIF3C contributes to mRNA circularization and translational regulation, particularly in contexts such as stem cell differentiation where a global increase in protein synthesis occurs .

How can I address potential data discrepancies when studying eIF3C across different cancer types?

Published studies demonstrate that eIF3C influences cancer development in multiple tumor types, but discrepancies in mechanistic details may arise. To address these inconsistencies:

• Cell type-specific effects:

  • Compare eIF3C knockdown effects across multiple cell lines from the same cancer type

  • Include both primary cells and established cell lines to identify possible cell line artifacts

  • Standardize experimental conditions (cell density, passage number, media composition)

• Methodological variation analysis:

  • Document and standardize knockdown efficiency measurements (protein vs. mRNA)

  • Use multiple orthogonal assays to confirm phenotypic effects

  • Apply consistent statistical analysis approaches across studies

• Cancer-specific mechanism comparisons:

  • Create a standardized panel of downstream effectors to analyze across cancer types

  • Include cell cycle regulators, apoptosis markers, and translation targets

  • Present data in normalized format to facilitate cross-cancer type comparison

Researchers should acknowledge these cancer-specific differences while identifying common mechanisms that may represent fundamental eIF3C functions applicable across multiple cancer types.

What are the key quality control steps for validating new eIF3C antibody lots?

Rigorous validation of new antibody lots is essential for experimental reproducibility. Implement these quality control steps:

• Initial validation:

  • Western blot with positive control lysates to confirm band at 110 kDa

  • Compare signal intensity with previous lot using serial dilutions

  • Assess specificity through eIF3C knockdown samples

• Cross-application testing:

  • If the antibody will be used for multiple applications (WB, IP, IF, IHC), validate in each

  • Document optimal working dilutions for each application

  • Compare performance across cell lines with known eIF3C expression levels

• Epitope verification:

  • Review vendor information on antibody epitope location

  • Consider potential post-translational modifications that might affect antibody recognition

  • For polyclonal antibodies, be aware of lot-to-lot variability in epitope recognition

• Reproducibility testing:

  • Perform replicate experiments across different days

  • Calculate coefficient of variation (CV) between replicates

  • Establish acceptance criteria (typically CV < 15% for quantitative applications)

Maintaining detailed records of these validation steps for each antibody lot provides crucial documentation for publications and ensures experimental reproducibility.

How can researchers effectively combine eIF3C antibodies with proximity labeling techniques to identify novel interactors?

Proximity labeling techniques offer powerful approaches to identify transient or context-dependent eIF3C interactors:

• BioID approach:

  • Generate expression constructs with eIF3C fused to BirA* biotin ligase

  • Express in target cells and induce biotinylation with biotin supplementation

  • Purify biotinylated proteins using streptavidin beads

  • Identify proteins by mass spectrometry

• APEX2-based proximity labeling:

  • Create eIF3C-APEX2 fusion constructs

  • Induce biotinylation with H₂O₂ and biotin-phenol (rapid, 1-minute labeling)

  • Isolate biotinylated proteins and identify by mass spectrometry

  • Validate key interactions with Co-IP and eIF3C antibodies

• Data analysis considerations:

  • Filter against BirA*/APEX2-only controls to remove non-specific biotinylation

  • Use quantitative proteomics with normalization against eIF3 core subunits

  • Apply empirical Bayes moderated t-tests for statistical analysis

  • Adjust p-values for multiple testing using Benjamini-Hochberg method

• Validation of novel interactions:

  • Confirm interactions by reciprocal Co-IP with eIF3C antibody

  • Test interaction dependence on RNA using RNase treatment

  • Assess co-localization by immunofluorescence

  • Evaluate functional relevance through knockdown of interaction partners

These approaches have successfully identified new interactors of eIF3 subunits, providing insights into translation regulation mechanisms beyond the canonical functions .

What are the future directions for eIF3C antibody applications in translational medicine?

Based on current research trajectories, several promising applications for eIF3C antibodies in translational medicine are emerging:

• Diagnostic applications:

  • Development of standardized IHC protocols for eIF3C detection in patient biopsies

  • Correlation of eIF3C expression levels with cancer progression and patient outcomes

  • Integration into multi-marker diagnostic panels for cancer classification

• Therapeutic targeting approaches:

  • Generation of function-blocking antibodies against eIF3C for therapeutic development

  • Design of antibody-drug conjugates targeting eIF3C-overexpressing cells

  • Combination approaches with existing cancer therapies to enhance efficacy

• Mechanism-based research:

  • Further characterization of eIF3C's role in 3'-UTR binding and translation regulation

  • Investigation of potential cancer-specific isoforms or modifications of eIF3C

  • Systems biology approaches to map the complete eIF3C interactome in different cellular contexts

• Technical innovations:

  • Development of phospho-specific eIF3C antibodies to study regulatory modifications

  • Creation of conformation-specific antibodies to detect functionally distinct forms

  • Integration with emerging spatial proteomics approaches